cardiovascular risk

  2. cardiovascular risk

OBICETRAPIB AS A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR: A CLINICAL AND PHARMACOLOGICAL REVIEW AND PROSPECTS FOR USE (LITERATURE REVIEW)

Dunaieva I. P., Kryvoshapka O. V., Pautina O. I., Doroshenko O. M., Shapoval O. M., Chorna N. S., Ruda N. G.
2026 Issue 1, 180 cardiovascular risk cholesteryl ester transfer protein dyslipidemia lipid-lowering therapy obicetrapib